BioWorld

March 17, 2003

Trimeris, Roche's First-In-Class HIV Drug, Fuzeon, Approved

The FDA cleared the accelerated approval application for Fuzeon, a first-in-class fusion inhibitor for HIV-1 developed by Trimeris Inc., and partner F. Hoffmann-La Roche Ltd. (BioWorld Today) Read More

The Medicines Co. Offering Gets $85.75M For Late-Stage Work

Activation Of Brain-Specific Genes Adds Data To Fragile X Syndrome, A Main Form Of Mental Retardation

Inspire Increases Share Amount, Raises $67.5M For Eye Products

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 11, 2025.

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...